Global Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market

Report ID : 1179 | Published : 2022-11-18 | Pages: 140 | Format: PDF/EXCEL

In recent years cancer has cancer has emerged as a major public health problem in the world and a few of the most common forms are breast cancer, lung cancer, prostate cancer and leukemia. Antibody drug conjugates (ADCs) signify a promising and an efficient strategy for targeted cancer therapy. ADCs are being developed as a new class of highly potent bio-pharmaceutical drugs, and characterized as an advanced therapeutic application that has collective properties of monoclonal antibodies (mAbs) with the potent small molecule drugs (cytotoxin). At present times, as research, development and approval of ADC-based technology moves forward, ADC-based chemotherapy drugs will impact the current chemotherapy market. It is further expected to improve the quality of life for cancer patients and influence research and development in other pharmaceutical markets.

The factor which is significantly boosting the growth of the global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies market is the rise in the incidence of cancer coupled with growing geriatric population. The increase in obese population and increasing research activities on antibody therapies is catalyzing the growth of Antibody drug conjugates industry. Also, increased investments by governments and private organizations for the preclinical research, and the cumulative research on oncology diseases are contributing to the growth of the global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies market. Increased focus of medical professionals on development of alternative therapies and treatments owing to the continually growing prevalence of cancer is projected to create growth opportunities during the forecast period.

The Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies market is categorized on the basis of ADC Linker Technologies, ADC Conjugation Technologies, application and region. On the basis of ADC Linker Technologies type, the market is segmented into Non-cleavable Linkers and Cleavable Linkers. Based on ADC Conjugation Technologies type, the market is segmented into Chemical Conjugation, and Enzymatic Conjugation. On the basis of application, the market is segmented into Leukemia, Lymphoma, Breast Cancer, Ovarian Cancer, Lung Cancer, and Brain Tumor. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, Asia-Pacific is expected to dominate the market during the analysis of forecast period.

The key players of this market include Seattle Genetics, Inc., ImmunoGen, Ambrx, Catalent Biologics, Immunomedics, Mersana Therapeutics, Sutro Biopharma, Iksuda Therapeutics, LegoChem Biosciences, LinXis, ADC therapeutics and Other Prominent Players.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market Snapshot

Chapter 4. Global Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By ADC Linker Technologies Types Estimates & Trend Analysis

5.1. By ADC Linker Technologies Types & Market Share, 2022 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By ADC Linker Technologies Types:

5.2.1. Non-cleavable Linkers

5.2.2. Cleavable Linkers

Chapter 6. Market Segmentation 2: By ADC Linker Technologies Type Estimates & Trend Analysis

6.1. By ADC Linker Technologies Type & Market Share, 2022 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By ADC Linker Technologies Type:

6.2.1. Chemical Conjugation

6.2.2. Enzymatic Conjugation

Chapter 7. Market Segmentation 3: By Application Estimates & Trend Analysis

7.1. By Application & Market Share, 2022& 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Application:

7.2.1. Leukemia

7.2.2. Lymphoma

7.2.3. Breast Cancer

7.2.4. Ovarian Cancer

7.2.5. Lung Cancer

7.2.6. Brain Tumor

Chapter 8. Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market  Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) estimates and forecasts By ADC Linker Technologies Types, 2022 - 2030

8.1.2. North America Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) estimates and forecasts By ADC Linker Technologies Type, 2022 - 2030

8.1.3. North America Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) estimates and forecasts by Application, 2022 - 2030

8.1.4. North America Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) estimates and forecasts by country, 2022 - 2030

8.2. Europe

8.2.1. Europe Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) By ADC Linker Technologies Types, 2022 - 2030

8.2.2. Europe Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) By ADC Linker Technologies Type, 2022 - 2030

8.2.3. Europe Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) estimates and forecasts by Application, 2022 - 2030

8.2.4. Europe Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) by country, 2022 - 2030

8.3. Asia Pacific

8.3.1. Asia Pacific Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) By ADC Linker Technologies Types, 2022 - 2030

8.3.2. Asia Pacific Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) By ADC Linker Technologies Type, 2022 - 2030

8.3.3. Asia Pacific Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) estimates and forecasts by Application, 2022 - 2030

8.3.4. Asia Pacific Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) by country, 2022 - 2030

8.4. Latin America

8.4.1. Latin America Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) By ADC Linker Technologies Types, (US$ Million)

8.4.2. Latin America Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) By ADC Linker Technologies Type, (US$ Million)

8.4.3. Latin America Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) estimates and forecasts by Application, 2022 - 2030

8.4.4. Latin America Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) By ADC Linker Technologies Types, (US$ Million)

8.5.2. Middle East & Africa Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) By ADC Linker Technologies Type, (US$ Million)

8.5.3. Middle East & Africa Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) estimates and forecasts by Application, 2022 - 2030

8.5.4. Middle East & Africa Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles 

9.2.1. Seattle Genetics, Inc.

9.2.2. ImmunoGen

9.2.3. Ambrx

9.2.4. Catalent Biologics

9.2.5. Immunomedics

9.2.6. Mersana Therapeutics

9.2.7. Sutro Biopharma

9.2.8. Iksuda Therapeutics

9.2.9. LegoChem Biosciences

9.2.10. LinXis

9.2.11. ADC therapeutics

9.2.12. NBE Therapeutics

9.2.13. Takeda Pharmaceutical Company Limited

9.2.14. Pfizer Inc

9.2.15. Hoffmann-La Roche Ltd

9.2.16. AbbVie Inc

9.2.17. AstraZeneca plc

9.2.18. Oxford BioTherapeutics Ltd.

9.2.19. Novartis AG

9.2.20. Angiex

9.2.21. Levena Biopharma

9.2.22. Synthon

9.2.23. Bayer Healthcare Pharmaceuticals

9.2.24. Zymeworks

9.2.25. Spirogen

9.2.26. Cerbios-Pharma

9.2.27. Other Prominent Players

Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Segmentation:

Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market by ADC Linker Technologies Type

  • Non-cleavable Linkers
  • Cleavable Linkers

Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market by ADC Conjugation Technologies Type

  • Chemical Conjugation
  • Enzymatic Conjugation

Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Based on Application

  • Leukemia
  • Lymphoma
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor

Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Based on Region

Europe

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America

  • U.S.
  • Canada

Asia Pacific

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients